An open-label, double tympanocentesis, single-center study of trimethoprim sulfametoxasole in children with acute otitis media.
Trimethoprim sulfamethoxasole has been recommended for the treatment of acute otitis media. In this double tympanocentesis study, children aged 3 to 48 months with acute otitis media received trimethoprim sulfamethoxasole twice daily (40 mg/kg/d) for 10 days. All children had a baseline tympanocentesis and in culture-positive children, tympanocentesis was repeated at the on-therapy visit. Of 89 children enrolled, 51 (57%) were clinically and bacteriologically evaluable. Bacteriologic eradication was achieved in 80% (42 of 52) of children, and overall clinical response at the end of therapy was 78%. Clinical success was 69% for culture-positive children versus 91% for culture-negative children at baseline tympanocentesis (P = 0.03). In this study, trimethoprim sulfamethoxasole clinical response was unsatisfactory, especially among culture-'positive children.
Soley
Carolina
C
Instituto de Atención Pediftrica, San José, Costa Rica.
Arguedas
Adriano
A
Guevara
Silvia
S
Loaiza
Cecilia
C
Rincón
Guillermo
G
Pérez
Alexandra
A
Brilla
Eduardo
E
Porras
Wendy
W
Arguedas
Jorge
J
Sierra
Hernán
H
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D010033:Otitis Media / Q000188:drug therapy*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination